Japan’s Role in Addressing Global Antimicrobial Resistance
August 11, 2016
On April 18, 2016, in Tokyo, the Washington-based Center for Strategic and International Studies (CSIS) Global Health Policy Center and the Tokyo-based Health and Global Policy Institute (HGPI) convened a U.S.-Japan expert meeting on antimicrobial resistance (AMR). AMR has the potential to undermine decades of progress against infectious diseases. The global spread of drug-resistant pathogens is already on the rise and, if left unchecked, will result in severe health and economic consequences worldwide. The gravity of this looming public health threat has attracted the attention of governments, international organizations like the World Health Organization, civil society, and the private sector. The Group of 7 (G7) made AMR a key health priority in 2015, and under Japan’s leadership, AMR continues to be a priority health agenda item for the G7 in 2016. In the lead-up to the May 2016 G7 Summit, meeting participants from the U.S. and Japanese governments, and from the private, academic, and nonprofit sectors, explored challenges to combating AMR and deliberated on ways the G7 could accelerate solutions. Speakers covered surveillance, antibiotic stewardship, infection prevention and control, and research and development of new antimicrobials and diagnostics. This report summarizes the April 18 meeting discussion and presents recommendations for G7 action.